Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer

NCT03386162 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT03386162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03386162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Terminated
Start date
March 15, 2018
Completion date
November 18, 2022
Enrollment
31 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, pi3k, alpelisib